Reproxalap turned down for a third time
Rejected by FDA
The FDA again declined to approve Aldeyra’s reproxalap drop for dry eye, pointing to study results that didn’t line up with each other.
Update, September 2026: Aldeyra says it will formally appeal the decision, and expects to file the appeal and meet with the FDA in the last three months of 2026. Reproxalap is still not approved. Source: Aldeyra Therapeutics press release, September 2026 (opens in a new tab)
Source: Fierce Biotech, March 2026 (opens in a new tab)